Increased OXPHOS activity precedes rise in glycolytic rate in H-RasV12/E1A transformed fibroblasts that develop a Warburg phenotype
© de Groof et al; licensee BioMed Central Ltd. 2009
Received: 23 March 2009
Accepted: 31 July 2009
Published: 31 July 2009
The Warburg phenotype in cancer cells has been long recognized, but there is still limited insight in the consecutive metabolic alterations that characterize its establishment. We obtained better understanding of the coupling between metabolism and malignant transformation by studying mouse embryonic fibroblast-derived cells with loss-of-senescence or H-RasV12/E1A-transformed phenotypes at different stages of oncogenic progression.
Spontaneous immortalization or induction of senescence-bypass had only marginal effects on metabolic profiles and viability. In contrast, H-RasV12/E1A transformation initially caused a steep increase in oxygen consumption and superoxide production, accompanied by massive cell death. During prolonged culture in vitro, cell growth rate increased gradually, along with tumor forming potential in in vitro anchorage-independent growth assays and in vivo tumor formation assays in immuno-deficient mice. Notably, glucose-to-lactic acid flux increased with passage number, while cellular oxygen consumption decreased. This conversion in metabolic properties was associated with a change in mitochondrial NAD+/NADH redox, indicative of decreased mitochondrial tricarboxic acid cycle and OXPHOS activity.
The high rate of oxidative metabolism in newly transformed cells is in marked contrast with the high glycolytic rate in cells in the later tumor stage. In our experimental system, with cells growing under ambient oxygen conditions in nutrient-rich media, the shift towards this Warburg phenotype occurred as a step-wise adaptation process associated with augmented tumorigenic capacity and improved survival characteristics of the transformed cells. We hypothesize that early-transformed cells, which potentially serve as founders for new tumor masses may escape therapies aimed at metabolic inhibition of tumors with a fully developed Warburg phenotype.
Carcinogenesis is a multi-step process that not only involves activation of oncogenes and/or inactivation of tumor suppressor genes , but also alterations in energy metabolism. Growth and viability of malignant cells is strongly dependent on their ability to adopt an altered metabolic profile that fulfills the synthetic and bioenergetic requirements for fast and uncontrolled growth. This metabolic phenotype is characterized by a shift from oxidative phosphorylation (OXPHOS) towards aerobic glycolysis as the main source of ATP production, a phenomenon first described by Otto Warburg .
The increased dependency of cancer cells on aerobic glycolysis is a well-recognized hallmark , but still relatively little is known about the factors that are in control during the early phases of the transformation process. Also, the issue whether or not this metabolic phenotype is an absolute prerequisite for advanced cancer progression is subject for debate . Carbohydrate metabolism must warrant sufficient supply of ATP for cell growth, but also maximize macromolecular biosynthesis . Intriguingly, cancer cells develop the ability to escape from senescence and apoptosis, processes in which glycolysis and mitochondrial pathways are actively engaged . Furthermore, tumor cells maximize antioxidant capacity via the glutathione system, which is coupled to increased flux through the glycolysis-coupled pentose phosphate pathway (PPP) . The question why tumor cells have a relatively high glycolytic rate compared to OXPHOS activity therefore goes well beyond the basics of which of the two processes is more efficient in terms of ATP production.
Carbohydrate metabolism has been studied extensively in the context of oncogene-induced cellular signaling, as mutations in metabolic enzyme-encoding genes themselves are rarely the direct cause of cancer . For example, increased glycolysis is triggered by activation of the PI3K/AKT signaling pathway [5, 9] or the p53 pathway . An important aspect that has been less well studied is how metabolism changes dynamically in a transforming cell population. The Warburg phenotype in solid tumors in vivo is thought to be the result of multiple adaptive changes in metabolism in response to both cell-internal and -external cues. Hence the conversion from a dysplasic cell towards a full-blown cancerous state  is not just caused by genetic changes alone.
The step-wise development and associated metabolic adjustments of patient tumor cells is difficult to monitor, as it is virtually impossible to obtain a population of founder cells from which the tumor originally evolved. We therefore developed populations of mouse embryonic fibroblasts (MEFs) to investigate how adaptations in glycolytic-mitochondrial capacity are accomplished during oncogenic transition. Specifically, we studied cells in an immortalized state or directly after oncogenic transformation by mutant H-RasV12 and E1A. These latter cells were followed during the step-wise conversion to a fully cancerous state in vitro and passage through immune-deficient mice in vivo, which gave us the opportunity to analyze metabolism in a broad window of tumor stages. We focused on the sequential order in which adaptations in glycolytic-mitochondrial capacity were accomplished under constant extrinsic conditions of culture medium and oxygenation.
Our data show a sharp increase in oxygen consumption and a high rate of formation of reactive oxygen species (ROS) directly after H-RasV12/E1A transformation, with a smooth transition towards higher glycolytic rates later during tumorigenic development. We hypothesize that the immediate increase in oxygen consumption and OXPHOS activity sets a new and delicate balance in cell fate specification, driving cells in an "adapt-or-perish" regime. Subsequent escape from this situation is associated with gain in survival characterized by a glycolytic switch even under ambient oxygen levels, an adaptation typical for the Warburg phenotype.
Generation of cell populations
Characteristics of primary, immortalized and tumorigenic cells in the panel
cell diameter (μm)
cell volume (pL)
number of colonies in soft agar
tumor size (mm2) in BALB/c nu/nu
cell doubling time (h)
Isolated from 12–14.5 day-old embyos
16.3 ± 1.0 (3)
2.6 ± 0.5 (3)
20.5 ± 0.7 (6)
Immortalized MEF (spontaneous)
Senescence bypass (3T3 passaging)
16.5 ± 0.7 (3)
2.7 ± 0.3 (3)
24.1 ± 1.1 (6)
Immortalized MEF (TBX2)
Retroviral transducton TBX2 gene
15.5 ± 0.3 (4)
2.1 ± 0.1 (4)
19.9 ± 0.9 (6)
MEF (low passage)
Retroviral transducton E1A/RasV12
11.0 ± 1.0 ** (4)
0.82 ± 0.2 ** (4)
131 ± 68 (5)
131 ± 62 (9)
16.8 ± 1.6 # (6)
RasV12/E1A MEF (high passage)
Retroviral transducton E1A/RasV12
10.1 ± 0.4 *** (4)
0.58 ± 0.1 *** (4)
880 ± 164 †† (5)
497 ± 182 † (9)
12.2 ± 0.7*** ‡ (8)
RasV12/E1A MEF (tumor)
RAS-HP passage in BALB/c nu/nu mice
10.5 ± 0.3 *** (3)
0.65 ± 0.1 *** (3)
705 ± 146 †† (7)
15.0 ± 1.0 ** (7)
Co-expression of mutant RasV12 and adenovirus E1A in primary mouse cells constitutes a model of multistep tumorigenesis for establishment of oncogenic cell populations . We used this principle to establish MEF populations at different phases of oncogenic transition towards a malignant phenotype via retroviral transduction of pLPC-E1A-ires-H-RasV12 in Prim-MEF cells at passage 2. The resulting cell pool was studied (i) directly after selection as in vitro cultivated cells (Ras-L ow P assage: 5–10), (ii) after prolonged passage in vitro (Ras-H igh P assage: > 25) or (iii) after injection of Ras-HP (p25) cells subcutaneously in the flank of immune-deficient mice and re-establishment as tumor cell populations in in vitro culture (Ras-TUM; between +3 and +10 passages after re-culturing). Each population was propagated as a mixed pool of cells with distinct viral DNA integration sites in the genome, and possibly differences in expression levels of the transforming transgenes. Thus, we avoided clonal analyses and excluded the possibility that one or few selective integrations of the transgene would dominate the phenotypic outcome.
Changes in cell morphology
Cell morphology in Prim-MEF, Imm-MEF and TBX2-MEF populations was largely similar, but introduction of H-RasV12/E1A induced prominent morphology changes and resulted in a marked reduction in cell diameter (Table 1; Additional file 1: Fig. S1; Fig. S2A). Notably, the cellular protein concentration (Additional file 1: Fig. S2B-C) was decreased in immortalized cells, while it tended to increase in H-RasV12/E1A transformed cells.
Growth characteristics of transformed cells
Lactic acid production in transformed cells
Steep increase in oxygen consumption rate immediately after transformation
The oxygen consumption rate was determined in normalized relative fluorescence units by analyzing trypsinized cells in BD Oxygen Biosensor multi-well plates, and subsequently corrected for protein content per cell (Fig. 3B; see Additional file 1: Fig. S3B). This parameter was relatively low in Prim-MEF and immortalized cell populations, but H-RasV12/E1A expression immediately induced a 5.6-fold increase in basal oxygen consumption rate per mg protein. Ras-HP cells showed 2.8-fold reduced oxygen consumption compared to Ras-LP, while the oxygen consumption of Ras-TUM cells was reverted to the level found in Prim-MEF cells.
Measurement of maximum oxygen consumption after uncoupling by FCCP revealed that mitochondria in Ras-LP cells function at 66% of their maximum respiratory capacity compared to only 25% in Prim-MEF and immortalized cells (Additional file 1: Fig. S4A-B). Oxygen consumption in all cell types was almost completely blocked by Complex V inhibitor oligomycin (Additional file 1: Fig. S4C), indicating that it was fully coupled to ATP production. Moreover, oxygen consumption was completely blocked by Complex III inhibitor myxothiazol and only marginally affected by extracellular supplementation of NADH, indicating that the vast majority of oxygen consumption occurred in mitochondria and was not due to membrane oxidase activity (Additional file 1: Fig. S4D), which significantly contributes to cellular oxygen consumption in a variety of tumor cell lines .
To verify these findings in an independent setting and to allow a direct calculation of fmoles oxygen consumed, we determined proton extrusion rate (indicative of anaerobic glycolytic rate) and oxygen consumption rate (indicative of mitochondrial OXPHOS) cells in adherent culture conditions using real time extracellular flux analysis . In accordance with lactic acid production, the normalized proton production rate (PPR; Fig. 3C) per cell increased step-wise in the transition Prim-MEF – Ras-LP – Ras-HP – Ras-TUM. Analysis of oxygen consumption rate in adherent cells (OCR; Fig. 3C) in real time showed drastically increased oxygen consumption in Ras-LP cells compared to Prim-MEF, which again appeared diminished in Ras-HP and Ras-TUM. Thus, H-RasV12/E1A transformation directly induced high OXPHOS activity, which gradually diminished during prolonged culture in vitro and passage through immune-deficient mice.
Expression levels of glycolytic and mitochondrial proteins
Protein expression levels in primary, immortalized and tumorigenic cell populations
Expression levels of proteins involved in cellular pyridine nucleotide balance
The setting of the cytosolic NAD+/NADH ratio determines the enzymatic rate of the GAPDH reaction, the LDH reaction, and the shuttling of NADH towards mitochondria via the malate-aspartate shuttle and is therewith an important determinant of pyruvate flux. We investigated if the alteration of flux through glycolytic and mitochondrial pathways was associated with changes in enzymes that determine the NAD+/NADH redox couple. Cytosolic malate dehydrogenase (MDH1) levels were two-fold higher in H-RasV12/E1A transformed than in non-transformed cells. In contrast, mitochondrial MDH (MDH2) levels appeared similar in all cell populations (Table 2; Additional file 1: Fig. S5C). Furthermore, the expression level of NAMPT, a key enzyme in the NAD+ salvage pathway and one of the main regulators of total cellular NAD level, increased immediately after H-RasV12/E1A expression. The induction of MDH1 and NAMPT could have important implications for the pyridine nucleotide balance.
Increased pyridine nucleotide levels in H-RasV12/E1A transformed cells
Steady state levels and redox state of pyridine nucleotides are important indicators and regulators for cell state and metabolic signaling activity . We studied the pyridine nucleotide levels by HPLC to reveal if adjustments in the balance between glycolysis and OXPHOS were indeed reflected in changes in steady-state levels of total cellular ATP, NAD+, NADH, NADP, or NADPH (see Additional file 2; Additional file 1: Fig. S6). This analysis showed a 30–40% increase in total cellular NAD(H) (NAD+ plus NADH) levels, but not NADP(H) (NADP+ plus NADPH) levels, in RasV12/E1A transformed populations relative to unchanged total cellular ATP level. Unfortunately, neither of the two HPLC analysis methods used allowed reliable quantification of the NAD+/NADH or NADP+/NADPH redox status due to methodological constrains.
Mitochondrial NAD+/NADH ratio is correlated with OXPHOS activity
Increased oxygen consumption is correlated to increased superoxide production
The increased oxygen consumption rate and the altered mitochondrial NAD(H)-redox setpoint in mitochondria prompted us to test if superoxide levels, as indicators of mitochondrial respiratory activity, were higher in Ras-LP cells. Superoxide levels per cell were monitored by HEt conversion to ethidium. Subsequent FACS analysis revealed two-fold higher levels in Ras-LP cells compared to Ras-HP and Ras-TUM cells on a per cell basis (Fig. 4D). Based on the absence of significant membrane oxidase activity (Additional file 1: Fig. S4D), we concluded that the majority of superoxide is generated in the mitochondria. In a control experiment, we showed that the switch to galactose in TBX2 cells has similar inducing effects on HEt fluorescence (Additional file 1: Fig. S7C).
We performed a comprehensive analysis of sequential metabolic changes that occur in a panel of cell populations with loss of cell-cycle arrest or increased tumorigenic potential. These analyses gave us new insight in the relation between oncogenic transformation and the development of the typical Warburg phenotype. The direct relatedness of the different cell pools – all pools were derived from the same primary MEFs ground state cell population – gave us a unique opportunity to do comparative profiling and highlight the early-late order of adaptive metabolic changes in energy metabolism that occur during solid tumor development.
Two genetically independent immortalization procedures had only minor effects on cell size, morphology, and carbohydrate metabolism, and yielded metabolic phenotypes with strong similarity to the original Prim-MEF cells. In contrast, H-RasV12/E1A transformation caused a prominent change from flattened to spherical appearance and smaller volume (see also ). Similar changes have been reported before for other transformed cell types [23, 24].
One of the most conspicuous observations in our study was that the metabolic phenotype initially switched to aerobic, OXPHOS-based, immediately after transformation. The augmented OXPHOS rate in Ras-LP cells was associated with increased total cellular NAD(H) levels, an altered mitochondrial NAD+/NADH setpoint, increased oxygen consumption and increased superoxide production. We think that OXPHOS induction in early transformed cells may be a general concept that precedes the well-documented Warburg effect or shift to aerobic glycolysis. The initial switch to aerobic metabolism has also been reported after oncogene-mediated transformation of human mesenchymal stem cells , human epithelial cells [26, 27] and human breast cancer cells . At this stage it is, however difficult to draw direct comparison between our findings in mouse cells and findings in the different human systems, as panels with related human cells lines comparable to our panel do not exist or were generated via use of increasing numbers of oncogenes . Future work, involving analyses of metabolic fate specification in panels with human cells from mesenchymal, epithelial, or progenitor-stem cell origin, will therefore be needed to verify the prediction of high OXPHOS activity in early transformed cells.
Importantly, our results indicate that environmental factors can exert strong influence on viability of tumor cells during the early phase of the transformation process. Anchorage-independent growth capacity of Ras-LP cells increased under low oxygen conditions, presumably by a direct suppressive effect on the high intrinsic and "unbalanced" mitochondrial activity or simply by better coupling of glycolytic-mitochondrial pathways. For better explanation and discrimination between these possibilities a detailed comparison of relative mitochondrial and glycolytic pathway activity in cells in colonies formed under ambient oxygen or in hypoxia would be imperative. Unfortunately, such pathway analysis on relatively small numbers of cells in soft agar in situ is currently technically not possible, so we have to leave this analysis for future work. If we may extrapolate these findings to the in vivo situation, we would predict that nutrient levels in the environment, including oxygen levels, may determine the fate of early dysplastic cells in tissues. In the light of our results, we predict that low oxygen or hypoxia would enhance their capacity to grow as tumors, as was already proposed in the model of Gatenby and Gillies .
The later trajectory of oncogenic transformation displayed by our cell panel involved a gradual shift towards higher anaerobic glycolysis rates over 20 passages in vitro and passage through immune-deficient mice, accompanied with clear gain in survival ability. We demonstrate here that the pools of cells that progress towards a tumorigenic phenotype go through a distinct series of adaptational changes. Although this metabolic rewiring may also be controlled by specific mutations in regulatory genes that become dominant in the entire pool, we consider it more likely that cell-intrinsic metabolic signaling mechanisms, acting within the windows set by the culture conditions (i.e. nutrient and O2 supply) used in our experiments, drive the gradual shift from OXPHOS to glycolysis. We draw this conclusion because we observed a similar stepwise drift in metabolic phenotype in a parallel series of cell populations that were independently derived from MEFs from mice with a combined defect in phosphotransfer enzymes CK-B and AK1 . At this point it is important to note that this entire transition trajectory occurred in continuous presence of 21% environmental oxygen and under constant medium conditions. Strikingly, H-RasV12/E1A expression only marginally affected protein expression levels of glycolytic, TCA and OXPHOS enzymes at all stages after transformation, implying that altered flux rates dominate and underlie the observed metabolic effects. The shift in mitochondrial NAD+/NADH ratio that we observed is in support of this model, as this ratio sets the flux rate of key metabolic reactions.
Adaptive changes in mitochondrial function, with or without further genetic programming, may provide growth- and survival advantage by conferring resistance to apoptotic cell death . Cells with electron flow through the ETC and enhanced glycolytic flux may perform best, as these are properties associated with reduced ROS production and increased ROS scavenging ability, respectively. ROS induced damage is a well-known factor in cell viability control . Indeed, in the H-RasV12/E1A cells mitochondria are the primary ROS source, as we observed a direct relationship between oxygen consumption and superoxide production. Indirect support for this relationship was also provided by our finding on glucose-galactose shift effects in TBX2-MEF cells.
We would like to emphasize that mechanisms other than those based on mitochondria-derived ROS effects could also explain the apparent coupling between tumor progression and increased glycolytic rate. Firstly, the metabolic infrastructure of cells could have changed due to Ras-induced alterations in cell morphology and cytoarchitecture. Cell surface changes, cell clustering, attachment and movement are processes that are coupled to actin cytoskeleton rearrangements. Bereiter-Hahn and co-workers  showed that changes in energy metabolism may result from rearrangements of the F-actin network, and conversely, that energy demand of motile actin-based structures is supplied predominantly by ATP derived from glycolysis. At the same time, mitochondrial dynamics are determined by a complex interplay between the inner membrane-matrix complex and cytoskeletal elements outside, possibly via F-actin and dynamin-related protein DRP1 . Upregulation of glycolysis or alteration of mitochondrial properties may thus be directly coupled to Ras-induced cytoskeletal remodeling, and fulfill new needs for development of anchorage independent growth, or other essential prerequisites for tumorigenic progression.
As another speculative possibility, there may also be a connection between cell cycle progression and the balance between glycolytic or oxidative metabolism. H-RasV12 induces cell cycle progression via enhanced G1 to S phase transition , and also the E1A oncoprotein induces S-phase via induction of p300/CBP and c-Myc . Recently, it was reported that slowly growing yeast cells in a low glucose environment exhibit a periodic metabolic cycle that alternates between glycolysis and respiration, where the cell division cycle is constrained to the reductive non-respiratory phase of this cycle, with DNA replication taking place only during the glycolytic phase [36, 37]. If extrapolation of the yeast model to the situation in mammalian cells is valid, our findings may suggest that glycolysis is the default metabolic pathway adapted by Ras-transformed cells with enhanced proliferation capacity.
Finally, our findings can also be explained by early alterations in NAD+/NADH setpoint, acting as driver for subsequent changes in tumorigenic conversion. We consider this an interesting possibility because we observed changes in set point level of NAD(H) (NAD+ plus NADH) metabolites and upregulation of NAMPT protein levels as parallel immediate early effects of H-RasV12/E1A transformation in our RAS-LP-HP-TUM series. Van der Veer et al.  reported that overexpression of NAMPT results in increased life span and resistance to oxidative stress. Our data show that total cellular NAD(H) levels increase upon cellular transformation and may relate to the simultaneous upregulation of the NAD-salvaging enzyme NAMPT at the protein level. Evidence is now accumulating that NAD+ levels, and/or redox state of the NAD+/NADH couple in cytosol, nucleus and mitochondria are key factors in transcriptional regulation [39, 40], modulation of growth-differentiation decisions in dividing cells , and survival control . Moreover, the need for NAD+ or NADH as essential co-factors in regulation of metabolic flux rates is already long known. While we regard our work as a first proof-of-concept it is clear that more study into these regulatory circuits – including those in human cells of different tissue origin – is necessary to draw definite conclusions about the control over early and late events in the Warburg transition.
We show that H-RasV12/E1A transformation of cells causes instantaneous and dramatic upregulation of mitochondrial ETC-OXPHOS activity, and not aerobic glycolysis. This brings newly transformed cells in a dangerous metabolic balance, reflected by a high rate of cell death. At this early stage, cells have a limited capacity for anchorage independent growth. Based on our findings we hypothesize that cells then traverse an "adapt-or-perish" period. Those that develop enhanced glycolysis and relatively low mitochondrial activity have increased survival chances, adapt further, and commonly develop the Warburg phenotype of tumorigenic cells. Our data predict that early-transformed cells, with high OXPHOS activity and the potential to serve as founders for new tumor masses, may be missed in positron emission tomography images or escape therapies aimed at metabolic inhibition of tumors with a fully developed Warburg phenotype.
For routine propagation, cells at all stages were kept under identical culture conditions with high nutrient and oxygen supply, with the exception of Ras-TUM cells, which were in an in vivo tumor environment for a four-week period. Cells were grown in DMEM (25 mM glucose, Invitrogen, Breda, The Netherlands) supplemented with 4 mM glutamine, 1 mM pyruvate and 10% Fetal Calf Serum (FCS, Greiner Bio-One, Alphen aan den Rijn, The Netherlands) in 21% environmental oxygen conditions or in 2% oxygen conditions where indicated. Primary MEFs were derived from E12.5–14 dpc mouse embryos  with a heterogeneous C57BL/6/129Ola background and frozen at passage 1. We subsequently derived all other cell populations from this pool of MEF cells as described in the Results section. In some experiments, cells were cultured in glucose-free DMEM (Invitrogen) supplemented with 10% dialyzed FBS and 10 mM galactose to stimulate oxidative phosphorylation . Details on retroviral transduction are available in Additional file 2.
Microscopy, cell morphology and cell size analysis
Protocols and equipment for microscopy and cell size analysis are available in the Additional file 2.
Soft agar assay and injection of cells in immune-deficient mice
Growth curves and metabolic profiling
For simultaneous determination of cell growth rate and lactic acid production, cells were seeded in 6-well plates. Medium was harvested and cells were counted at 24 h, 48 h, and 72 h. Lactic acid levels were determined using the Amplex Red glucose/glucose oxidase kit (Molecular Probes, Leiden, The Netherlands), with lactate oxidase (Sigma-Aldrich) in the reaction instead of glucose oxidase. Growth curves, cell doubling time and average cell number per hour were calculated in the exponential growth phase (24–72 hrs) to obtain metabolite production/consumption per average cell in culture. These numbers were converted to metabolite production/consumption per mg.
Cells were trypsinized, counted, resuspended in culture medium and transferred to the BD Oxygen Biosensor 384 multi-well plates (Becton Dickinson, Erembodegem-Aalst, Belgium). Cellular oxygen consumption was determined in culture medium, and in medium supplemented with FCCP (2 μM), oligomycin (2.5 μM), myxothiazol (1 μM) or NADH (1 μM; all Sigma-Aldrich). Fluorescence (485 nm excitation, 612 nm emission) was recorded in a POLARstar Optima Fluorescence polarization plate reader (BMG Labtech, IJsselstein, The Netherlands) in 2-min intervals at 37°C for 4 hrs. The maximum slope of fluorescence units/min was calculated and converted into normalized relative fluorescence units (NRFU/min).
Real-time metabolic analysis
Simultaneous multiparameter metabolic analysis of cell populations in culture was performed in the Seahorse XF24 extracellular flux analyzer (Seahorse Bioscience, Billerica, MA, USA) as described by Wu et al. . All six cell lines were cultured in growth medium for 48 hours in plate before real-time metabolic analysis. At the start of the assay, growth medium was removed and replaced with DMEM medium containing 5% FBS (free of bicarbonate). Basal OCR (oxygen consumption rate) and PPR (proton production rate) of the cells were measured repeatedly in 30 minutes. After XF assay, cells were harvested by trypsin-EDTA treatment and counted on ViCell (Beckman Coulter, Fullerton, CA, USA). The number of cells per well were used to normalize OCR and PPR.
Lysate preparation and Western blot
For HPLC analysis, six 10 cm dishes (Prim, Imm-MEF, TBX2-MEF) or 6-cm dishes (other cell lines) were cultured. In each experiment, three plates were used for cell counts; the other three for metabolite extraction using the sample preparation method of Fiehn (MeOH/CHCl3 extraction method, see Additional file 2). We repeated the entire experiment using a perchlorid acid extraction sample preparation method. This method allowed parallel protein quantification using the Pierce BCA kit (Pierce, Etten-Leur, The Netherlands). Further details of the HPLC instrumentation and the experimental procedures are available in Additional file 2.
Microscopic measurement of NAD(P)H autofluorescence
Analysis of superoxide production
Cell cultures were incubated in HEPES-Tris medium containing 10 μM hydroethidine (HEt; Molecular Probes) for 10 min at 37°C . The reaction was stopped by thorough washing of the cells with PBS to remove excess HEt. After trypsinization and fixation in 2% paraformaldehyde, cells were washed and transferred to FACS tubes. Ethidium fluorescence was elicited by excitation at 488 nm and the emission signal detected at 540–600 nm or > 670 nm using FACScan equipment (Becton Dickinson).
Statistical analyses were performed by one-way ANOVA and Bonferroni's multiple comparisons test. Pairwise comparisons were made between Prim-MEF and all other cell populations, or between Ras-LP and the other two Ras-transformed populations. Other statistical analysis methods are mentioned in the text.
Mitochondrial Complex I
Electron transport chain
Mouse embryonic fibroblast
Nicotinamide mononucleotide phosphoribosyl transferase
Normalized relative fluorescence units
Oxygen consumption rate
Pentose phosphate pathway
Proton production rate
Reactive oxygen species.
Retroviral vector pLPC-E1A-ires-H-rasV12 was a kind gift of Dr. M. Serrano, Spanish National Cancer Center, Madrid, Spain. Retroviral vector pBabe-TBX2 was a kind gift of Dr. M. Van Lohuizen, The Netherlands Cancer Institute, Amsterdam, The Netherlands. We thank Dr. Helma Pluk for performing the Scanning Electron Microscopy. This study was supported by grant KUN 2004-3125 from the Dutch Cancer Society KWF Kanker Bestrijding to B.W.
- Hanahan D, Weinberg RA: The Hallmarks of Cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9View ArticlePubMedGoogle Scholar
- Warburg O: On the Origin of Cancer Cells. Science. 1956, 123: 309-314. 10.1126/science.123.3191.309View ArticlePubMedGoogle Scholar
- Kroemer G, Pouyssegur J: Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell. 2008, 13: 472-482. 10.1016/j.ccr.2008.05.005View ArticlePubMedGoogle Scholar
- Zu XL, Guppy M: Cancer metabolism: facts, fantasy, and fiction. Biochem Biophys Res Commun. 2004, 313: 459-465. 10.1016/j.bbrc.2003.11.136View ArticlePubMedGoogle Scholar
- DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB: The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation. Cell Metab. 2008, 7: 11-20. 10.1016/j.cmet.2007.10.002View ArticlePubMedGoogle Scholar
- Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, Peters G, Martinez D, Carnero A, Beach D: Glycolytic Enzymes Can Modulate Cellular Life Span. Cancer Res. 2005, 65: 177-185.PubMedGoogle Scholar
- Bui T, Thompson CB: Cancer's sweet tooth. Cancer Cell. 2006, 9: 419-420. 10.1016/j.ccr.2006.05.012View ArticlePubMedGoogle Scholar
- Eng C, Kiuru M, Fernandez MJ, Aaltonen LA: A role for mitochondrial enzymes in inherited neoplasia and beyond. Nat Rev Cancer. 2003, 3: 193-202. 10.1038/nrc1013View ArticlePubMedGoogle Scholar
- Plas DR, Thompson CB: Akt-dependent transformation: there is more to growth than just surviving. Oncogene. 2005, 24: 7435-7442. 10.1038/sj.onc.1209097View ArticlePubMedGoogle Scholar
- Bensaad K, Vousden KH: p53: new roles in metabolism. Trends Cell Biol. 2007, 17: 286-291. 10.1016/j.tcb.2007.04.004View ArticlePubMedGoogle Scholar
- Gillies RJ, Robey I, Gatenby RA: Causes and consequences of increased glucose metabolism of cancers. J Nucl Med. 2008, 49 (Suppl 2): 24S-42S. 10.2967/jnumed.107.047258View ArticlePubMedGoogle Scholar
- Todaro GJ, Green H: Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. J Cell Biol. 1963, 17: 299-313. 10.1083/jcb.17.2.299PubMed CentralView ArticlePubMedGoogle Scholar
- Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ: Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell. 1997, 91: 649-659. 10.1016/S0092-8674(00)80452-3View ArticlePubMedGoogle Scholar
- Vasseur S, Malicet C, Calvo E, Labrie C, Berthezene P, Dagorn J, Iovanna J: Gene expression profiling by DNA microarray analysis in mouse embryonic fibroblasts transformed by rasV12 mutated protein and the E1A oncogene. Mol Cancer. 2003, 2: 19- 10.1186/1476-4598-2-19PubMed CentralView ArticlePubMedGoogle Scholar
- DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, Thompson CB: Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA. 2007, 104: 19345-19350. 10.1073/pnas.0709747104PubMed CentralView ArticlePubMedGoogle Scholar
- Herst PM, Berridge MV: Cell surface oxygen consumption: A major contributor to cellular oxygen consumption in glycolytic cancer cell lines. Biochim Biophys Acta. 2007, 1767: 170-177. 10.1016/j.bbabio.2006.11.018View ArticlePubMedGoogle Scholar
- Wu M, Neilson A, Swift AL, Moran R, Tamagnine J, Parslow D, Armistead S, Lemire K, Orrell J, Teich J: Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am J Physiol Cell Physiol. 2007, 292: C125-136. 10.1152/ajpcell.00247.2006View ArticlePubMedGoogle Scholar
- Hochachka PW: Intracellular convection, homeostasis and metabolic regulation. J Exp Biol. 2003, 206: 2001-2009. 10.1242/jeb.00402View ArticlePubMedGoogle Scholar
- Pollak N, Dolle C, Ziegler M: The power to reduce: pyridine nucleotides – small molecules with a multitude of functions. Biochem J. 2007, 402: 205-218. 10.1042/BJ20061638PubMed CentralView ArticlePubMedGoogle Scholar
- Levitt JM, Baldwin A, Papadakis A, Puri S, Xylas J, Munger K, Georgakoudi I: Intrinsic fluorescence and redox changes associated with apoptosis of primary human epithelial cells. J Biomed Opt. 2006, 11: 064012- 10.1117/1.2401149View ArticlePubMedGoogle Scholar
- Marroquin LD, Hynes J, Dykens JA, Jamieson JD, Will Y: Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol Sci. 2007, 97: 539-547. 10.1093/toxsci/kfm052View ArticlePubMedGoogle Scholar
- Russo J, Tait L, Russo I: Morphological expression of cell transformation induced by c-Ha-ras oncogene in human breast epithelial cells. J Cell Sci. 1991, 99: 453-463.PubMedGoogle Scholar
- Alexandrova AY, Kopnin PB, Vasiliev JM, Kopnin BP: ROS up-regulation mediates Ras-induced changes of cell morphology and motility. Exp Cell Res. 2006, 312: 2066-2073. 10.1016/j.yexcr.2006.03.004View ArticlePubMedGoogle Scholar
- Goldberg L, Kloog Y: A Ras Inhibitor Tilts the Balance between Rac and Rho and Blocks Phosphatidylinositol 3-Kinase-Dependent Glioblastoma Cell Migration. Cancer Res. 2006, 66: 11709-11717. 10.1158/0008-5472.CAN-06-1878View ArticlePubMedGoogle Scholar
- Funes JM, Quintero M, Henderson S, Martinez D, Qureshi U, Westwood C, Clements MO, Bourboulia D, Pedley RB, Moncada S, Boshoff C: Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production. Proc Natl Acad Sci USA. 2007, 104: 6223-6228. 10.1073/pnas.0700690104PubMed CentralView ArticlePubMedGoogle Scholar
- Telang S, Lane AN, Nelson KK, Arumugam S, Chesney J: The oncoprotein H-RasV12 increases mitochondrial metabolism. Mol Cancer. 2007, 6: 77- 10.1186/1476-4598-6-77PubMed CentralView ArticlePubMedGoogle Scholar
- Ramanathan A, Wang C, Schreiber SL: Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci USA. 2005, 102: 5992-5997. 10.1073/pnas.0502267102PubMed CentralView ArticlePubMedGoogle Scholar
- Richardson A, Yang C, Osterman A, Smith J: Central carbon metabolism in the progression of mammary carcinoma. Breast Cancer Res Treat. 2008, 110 (2): 297-307. 10.1007/s10549-007-9732-3PubMed CentralView ArticlePubMedGoogle Scholar
- Gatenby RA, Gillies RJ: A microenvironmental model of carcinogenesis. Nat Rev Cancer. 2008, 8: 56-61. 10.1038/nrc2255View ArticlePubMedGoogle Scholar
- Van Horssen R, Janssen E, Peters W, Pasch van de L, Te Lindert MM, van Dommelen MM, Linssen PC, Ten Hagen TL, Fransen JA, Wieringa B: Modulation of cell motility by spatial repositioning of enzymatic ATP/ADP exchange capacity. J Biol Chem. 2009, 284: 1620-1627. 10.1074/jbc.M806974200View ArticlePubMedGoogle Scholar
- Kwong JQ, Henning MS, Starkov AA, Manfredi G: The mitochondrial respiratory chain is a modulator of apoptosis. J Cell Biol. 2007, 179: 1163-1177. 10.1083/jcb.200704059PubMed CentralView ArticlePubMedGoogle Scholar
- Bereiter-Hahn J, Stubig C, Heymann V: Cell Cycle-Related Changes in F-Actin Distribution Are Correlated with Glycolytic Activity. Exp Cell Res. 1995, 218: 551-560. 10.1006/excr.1995.1190View ArticlePubMedGoogle Scholar
- Bereiter-Hahn J, Voth M, Mai S, Jendrach M: Structural implications of mitochondrial dynamics. Biotechnol J. 2008, 3: 765-780. 10.1002/biot.200800024View ArticlePubMedGoogle Scholar
- Meloche S, Pouyssegur J: The ERK1//2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene. 2007, 26: 3227-3239. 10.1038/sj.onc.1210414View ArticlePubMedGoogle Scholar
- Baluchamy S, Sankar N, Navaraj A, Moran E, Thimmapaya B: Relationship between E1A binding to cellular proteins, c-myc activation and S-phase induction. Oncogene. 2006, 26: 781-787. 10.1038/sj.onc.1209825View ArticlePubMedGoogle Scholar
- Chen Z, Odstrcil EA, Tu BP, McKnight SL: Restriction of DNA Replication to the Reductive Phase of the Metabolic Cycle Protects Genome Integrity. Science. 2007, 316: 1916-1919. 10.1126/science.1140958View ArticlePubMedGoogle Scholar
- Tu BP, Mohler RE, Liu JC, Dombek KM, Young ET, Synovec RE, McKnight SL: Cyclic changes in metabolic state during the life of a yeast cell. Proc Natl Acad Sci USA. 2007, 104: 16886-16891. 10.1073/pnas.0708365104PubMed CentralView ArticlePubMedGoogle Scholar
- Veer van der E, Ho C, O'Neil C, Barbosa N, Scott R, Cregan SP, Pickering JG: Extension of Human Cell Lifespan by Nicotinamide Phosphoribosyltransferase. J Biol Chem. 2007, 282: 10841-10845. 10.1074/jbc.C700018200View ArticlePubMedGoogle Scholar
- Zheng L, Roeder RG, Luo Y: S phase activation of the histone H2B promoter by OCA-S, a coactivator complex that contains GAPDH as a key component. Cell. 2003, 114: 255-266. 10.1016/S0092-8674(03)00552-XView ArticlePubMedGoogle Scholar
- Fjeld CC, Birdsong WT, Goodman RH: Differential binding of NAD+ and NADH allows the transcriptional corepressor carboxyl-terminal binding protein to serve as a metabolic sensor. Proc Natl Acad Sci USA. 2003, 100: 9202-9207. 10.1073/pnas.1633591100PubMed CentralView ArticlePubMedGoogle Scholar
- Smith J, Ladi E, Mayer-Proschel M, Noble M: Redox state is a central modulator of the balance between self-renewal and differentiation in a dividing glial precursor cell. Proc Natl Acad Sci USA. 2000, 97: 10032-10037. 10.1073/pnas.170209797PubMed CentralView ArticlePubMedGoogle Scholar
- Yang H, Yang T, Baur JA, Perez E, Matsui T, Carmona JJ, Lamming DW, Souza-Pinto NC, Bohr VA, Rosenzweig A: Nutrient-Sensitive Mitochondrial NAD+ Levels Dictate Cell Survival. Cell. 2007, 130: 1095-1107. 10.1016/j.cell.2007.07.035PubMed CentralView ArticlePubMedGoogle Scholar
- Hogan B, Beddington R, Costantini F, Lacy E: Preparing mouse embryo fibroblasts. Manipulating the Mouse Embryo. 1994, 260-261. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory PressGoogle Scholar
- Rossignol R, Gilkerson R, Aggeler R, Yamagata K, Remington SJ, Capaldi RA: Energy Substrate Modulates Mitochondrial Structure and Oxidative Capacity in Cancer Cells. Cancer Res. 2004, 64: 985-993. 10.1158/0008-5472.CAN-03-1101View ArticlePubMedGoogle Scholar
- de Groof A, Oerlemans F, Jost C, Wieringa B: Changes in glycolytic network and mitochondrial design in creatine kinase-deficient muscles. Muscle Nerve. 2001, 24: 1188-1196. 10.1002/mus.1131View ArticlePubMedGoogle Scholar
- Verkaart S, Koopman WJH, Cheek J, Vries van Emst-de SE, Heuvel van den LWPJ, Smeitink JAM, Willems PHGM: Mitochondrial and cytosolic thiol redox state are not detectably altered in isolated human NADH:ubiquinone oxidoreductase deficiency. Biochim Biophys Acta. 2007, 1772: 1041-1051.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.